The terminology matters because extracellular vesicles are not a single product. They are lipid-bilayer particles formed through distinct processes, including endosomal release, plasma-membrane budding and fragmentation of apoptotic cells. The review follows MISEV2023 guidance by using the general term extracellular vesicle, or EV, unless the origin of a preparation is established. Small EVs, commonly defined operationally as particles below approximately 200 nanometres, are also called sEVs, but their small size does not prove that they arose inside endosomes. Likewise, morphology, electron microscopy and detection of proteins such as CD9, CD63 and CD81 alone cannot establish exosome biogenesis. This distinction is important for interpreting which biological effects can reasonably be attributed to EVs rather than to co-isolated proteins, RNA, lipids or other material.

Clinical observations point toward both diagnostic and disease-mechanistic possibilities, while falling short of establishing clinical utility. One study reported increased annexin V-positive platelet microparticles in women with PCOS. Another compared follicular-fluid particle fractions and granulosa-cell small-RNA profiles in women with and without PCOS, finding that body-mass index and the sampled particle fraction influenced the apparent RNA signatures. The six upregulated and sixteen downregulated small RNAs reported in that comparison came from an overall follicular-fluid analysis rather than from an exclusively small-EV population. Follicular fluid is usually collected during oocyte retrieval, making it an invasive specimen rather than a non-invasive screening tool. Circulating EVs are more compatible with accessible sampling, but disease-specific sensitivity, specificity and added clinical value have not yet been established.

Functional experiments suggest that follicular EVs can carry pathological as well as potentially protective signals. Elevated EV-associated LIPE-AS1 was linked to altered steroid metabolism and impaired oocyte maturation through a LIPE-AS1/miR-4306/LHCGR regulatory axis, while adipocyte-derived EV-associated miR-26b was reported to promote cumulus-cell apoptosis by targeting JAG1. In an IVF/ICSI cohort, higher miR-143-5p in follicular-fluid EVs suppressed RASAL2 and promoted granulosa-cell proliferation; inhibiting the miRNA in a letrozole-induced rat model improved ovarian and hormonal abnormalities. Because increased proliferation can coexist with arrested follicular development, the finding does not make miR-143-5p a therapeutic supplement. Instead, it supports its candidacy as a biomarker or inhibitory target, subject to independent validation, prespecified thresholds and assessment beyond standard clinical variables.

Several experimental interventions suggest that stromal-cell-derived EVs can alter cellular pathways associated with ovarian dysfunction. Umbilical-cord stromal-cell EVs reduced METTL3 expression, PINK1 messenger-RNA m6A modification and PINK1 transcript stability in DHEA-treated KGN cells and mice, suppressing excessive PINK1/Parkin-associated mitophagy and apoptosis. Overexpression of METTL3 partly reversed the effect. Adipose stromal-cell EV-associated miR-323-3p acted through PDCD4 to promote cumulus-cell proliferation and reduce apoptosis. Another study involving follicular-fluid EV-associated miR-18b-5p proposed PTEN suppression and PI3K/Akt/mTOR activation in KGN cells and letrozole-induced rats; treatment was associated with lower FSH, LH and testosterone and higher estradiol. These studies connect vesicles to defined mechanisms, but they do not show that unselected patient follicular EVs are uniformly protective.

Metabolic effects provide a second route of potential benefit. In PCOS rats, adipose stromal-cell EVs transferred miR-21-5p to the liver, reduced BTG2 and activated IRS1/AKT signalling; metabolic improvement accompanied changes in ovarian phenotype and fertility. This supports an extraovarian mechanism rather than selective ovarian delivery. Brown-adipose-tissue EVs administered to letrozole-induced mice were reported to improve insulin resistance, estrous cyclicity and fertility, with lower LH and testosterone, reduced ovarian STAT3 and increased GPX4. Menstrual-blood stromal-cell EVs improved mitochondrial biogenesis, oxidative-stress measures and estradiol-related endpoints in granulosa cells isolated from treated rats, but that experiment did not involve administration to intact animals or demonstrate fertility rescue. Differences in source, cargo, dose, route and model mean that similar endpoints across studies cannot establish equivalent efficacy.

Dose and delivery also complicate the therapeutic picture. In an estradiol-valerate mouse model, adipose stromal-cell-derived exosome-like nanovesicles were associated with a lower LH/FSH ratio, higher estradiol and changes in FOXO3, Map1lc3b and SF-1 expression. The strongest histological response occurred at 75 micrograms per kilogram, whereas 100 micrograms per kilogram was associated with inflammation and partial tissue degeneration. The observation cautions against assuming that greater exposure is necessarily safer or more effective. Engineered small EVs have also been used to improve delivery rather than to demonstrate general ovarian homing. A CD63-binding peptide, CP05, was used to attach the PI3K agonist 740Y-P to umbilical-cord stromal-cell sEVs; intravenous treatment in DHEA-induced mice improved reproductive and glucose-insulin endpoints relative to model controls. The study found no difference in ovarian internalization of modified and unmodified sEVs at the assessed time, so the result supports enhanced payload delivery rather than a general increase in EV targeting.

Evidence concerning fertility remains mixed and strongly dependent on biological context. Follicular EVs from nonhyperandrogenic PCOS patients impaired maturation of mouse oocytes exposed to the preparations, with increased oxidative stress and mitochondrial and spindle abnormalities. The selected phenotype and cross-species assay limit generalization, but the experiment demonstrates that patient-derived follicular vesicles may transmit harmful signals. By contrast, Wharton’s-jelly stromal-cell conditioned medium and EVs both improved selected in-vitro maturation outcomes in mouse oocytes, although conditioned medium generally produced greater benefit and significant restoration of maturation-related gene expression was reported mainly in conditioned-medium groups. Adjacent studies involving chemotherapy-related ovarian injury, premature ovarian insufficiency or thin endometrium are not direct PMOS treatment evidence. Any future strategy for PMOS-associated infertility would need to assess oocyte competence, endometrial receptivity and implantation rather than infer fertility from cell viability alone.

The review’s descriptive appraisal of five studies with accessible main texts highlights weaknesses in reporting against MISEV2023 recommendations. Two described morphology and particle size without an EV-associated protein panel. Two reported EV-associated proteins but did not describe a negative-marker or contaminant panel, while the engineered sEV study included positive and cellular negative markers but could benefit from broader cytosolic-marker and co-isolate assessments. These are reporting limitations, not proof that vesicles were absent; supplementary or inaccessible information could alter individual judgments. Relevant controls include EV-depleted fractions, medium processed without producer cells, cargo loss-of-function and rescue experiments, and labeling controls for uptake studies. Particle numbers and total preparation protein are also different dosing measures and should not be treated as interchangeable.

Translation also requires direct measurement of where administered vesicles travel and how long they remain active. Experimental biodistribution indicates substantial hepatic and splenic accumulation, with distribution influenced by cell source, dose, route and targeting strategy. Studies should therefore compare ovarian exposure with liver, spleen and other organs, assess retention and clearance, and include free-label controls. Engineered products require separate measurements of loading efficiency, removal of unbound drug, batch consistency and carrier-versus-cargo effects. Repeated-dose safety should address inflammation, endocrine perturbation, ovarian reserve, ectopic proliferation and offspring outcomes. The review’s central conclusion is that extracellular vesicles connect ovarian cell communication with systemic metabolism and offer biomarker candidates, inhibitory targets and experimental delivery systems, but their effects are source- and context-specific. Independent clinical validation, standardized characterization, quantitative biodistribution and long-term reproductive safety remain the decisive steps between today’s animal models and patient care.

Subject of Research: Extracellular-vesicle mechanisms, biomarkers and experimental therapies in polyendocrine metabolic ovarian syndrome

Article Title: Research progress of extracellular vesicles in PMOS: molecular mechanisms, diagnostic value, and therapeutic strategies

Article References: Qi, L., Jiang, Y., Han, Y., Feng, C., Jia, L., & Zhang, Y. (2026). Research progress of extracellular vesicles in PMOS: molecular mechanisms, diagnostic value, and therapeutic strategies. Frontiers in Endocrinology, 17, Article 1976561. https://doi.org/10.3389/fendo.2026.1976561

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1976561

Keywords: extracellular vesicles, polyendocrine metabolic ovarian syndrome, PCOS, ovarian dysfunction, biomarkers, mesenchymal stromal cells, granulosa cells, oocyte maturation, mitochondrial signaling, insulin resistance, Research, progress

The new study, published in Frontiers in Animal Science, examined Duolang sheep, an indigenous breed from the Xinjiang region prized for its early sexual maturity, year-round estrous cycles, and relatively high reproductive output. First estrus in this breed typically arrives at around five months of age, making the animals an attractive model for dissecting the molecular events that accompany the onset of fertility. The researchers focused on ESR2, the gene encoding estrogen receptor beta, a protein abundant in ovarian granulosa cells that mediates estrogen’s local effects on follicular development, granulosa cell differentiation, and ovulation. When ESR2 function is lost in experimental animals, granulosa cells respond poorly to gonadotropins, follicular maturation falters, and ovulation is impaired.

The logic behind the study rests on a well-established principle of epigenetics. DNA methylation, the addition of methyl groups to cytosine bases within CpG dinucleotides, tends to cluster in promoter regions called CpG islands. When these islands are heavily methylated, transcription factors may struggle to bind and chromatin may become less accessible, generally suppressing gene transcription. Because epigenetic regulation has already been implicated in the developmental activation of the female reproductive axis, the team asked a straightforward question: does methylation of the ESR2 promoter change as Duolang ewes pass through puberty, and do those changes track the gene’s activity?

To find out, the researchers collected ovarian tissue from fifteen healthy ewes divided into three groups of five: prepubertal animals at ninety days of age, pubertal animals sampled within twenty-four hours of their first observed estrus, and early postpubertal animals sampled within seven days after estrous behavior subsided. Puberty was defined behaviorally, by voluntary acceptance of mounting, restlessness, increased vocalization, vulvar swelling, and mucous discharge during daily ram-exposure checks. The team first cloned and sequenced a 2,871-base-pair stretch of the ESR2 promoter, identifying four candidate transcription start sites, a single TATA box, sixty-seven predicted transcription factor binding sites, and two CpG islands. They then used bisulfite sequencing, a technique that converts unmethylated cytosines to uracil while leaving methylated cytosines intact, to measure methylation at nine sites in the first CpG island and twenty-two sites in the second.

The results revealed a striking asymmetry between the two regulatory regions. Methylation of CpG island 1 declined steadily across the three stages, falling from 82.22 percent in prepubertal ovaries to 78.71 percent at puberty and 71.11 percent in the early postpubertal period, an absolute drop of more than eleven percentage points. CpG island 2 behaved differently, dipping from 79.09 percent to 74.45 percent at puberty before rebounding to 79.82 percent afterward, a level significantly higher than the pubertal value. Meanwhile, ESR2 messenger RNA expression climbed progressively: significantly higher at puberty than before it, and significantly higher still after puberty than at either earlier stage.

The correlation analysis sharpened the picture. In the prepubertal group, methylation of CpG island 1 showed only a weak, statistically insignificant relationship with ESR2 expression. But in the pubertal and postpubertal groups, the correlation turned strongly negative, with coefficients of -0.956 and -0.969 respectively, meaning that lower methylation was consistently paired with higher gene expression. At the level of individual CpG sites, the story grew more nuanced: some positions within each island showed nominal associations with expression in one direction, others in the opposite direction, and the average methylation of an island did not always capture what was happening at specific sites. The authors are careful to note that these site-level findings rest on unadjusted P values and should be treated as candidate associations rather than confirmed regulatory elements.

To probe whether demethylation could actually drive ESR2 expression, the team turned to cultured ovarian granulosa cells, verified as more than 95 percent pure by immunofluorescent staining for the follicle-stimulating hormone receptor. Treating the cells with 0.5 micromolar 5-aza-2′-deoxycytidine, a drug that inhibits DNA methyltransferases and strips methyl groups genome-wide, significantly increased ESR2 mRNA expression after thirty-six hours and boosted cell viability at later time points. On its face, the experiment seems to close the loop: remove methylation, and the gene wakes up.

But the researchers are refreshingly candid about the limits of that inference. Because 5-Aza-dC acts globally rather than on the ESR2 promoter specifically, and because promoter methylation was not remeasured after treatment, the rise in expression cannot be attributed directly to demethylation of either CpG island. Nor was the ERβ protein itself quantified, leaving open whether the transcriptional change translated into more receptor. The authors also acknowledge a series of constraints on the tissue study: only five animals per stage, behavioral rather than endocrine confirmation of pubertal status, just five bisulfite-sequenced clones per animal per island, and whole-ovary samples in which shifts in the proportions of granulosa, theca, stromal, and luteal cells could masquerade as regulatory changes. The expression stage-pattern, they note, may equally reflect changes in follicular composition and the ovarian endocrine environment rather than a causal role for ESR2 in triggering puberty.

Context from other species both supports and complicates the interpretation. In Holstein cows, prenatal heat exposure has been linked to site-specific methylation of the ESR2 untranslated region and altered expression of ovarian steroid receptors in adult dominant follicles, hinting that this gene’s epigenetic state is sensitive to developmental conditions. An integrated methylome and transcriptome analysis of Hu sheep ovaries found a negative relationship between methylation near transcription start sites and gene expression, and large-scale demethylation has been observed in proliferating mouse granulosa cells during follicular development. Genome-wide studies of gilt ovaries and goat hypothalami, however, show that methylation changes during reproductive maturation are tissue-specific, region-specific, and stage-dependent, meaning the declining pattern seen in Duolang CpG island 1 should not be assumed to be a universal signature of puberty.

What the study ultimately delivers is a well-mapped starting point rather than a mechanism. It establishes that the ESR2 promoter carries dynamic, stage-specific methylation patterns in a breed defined by early fertility, that one of those patterns inversely tracks gene expression precisely when the ovary is transitioning to reproductive activity, and that pharmacological demethylation is associated with increased ESR2 transcription in granulosa cells. The candidate CpG sites identified here, particularly those within island 1 that correlated negatively with expression, now form a shortlist for promoter-reporter assays, targeted methylation editing, and transcription-factor binding experiments. If those follow-up studies hold up, epigenetic markers of reproductive maturation could eventually inform selection programs aimed at breeding sheep that reach puberty sooner and reproduce more prolifically, turning a chemical footnote on DNA into a practical tool for livestock genetics.

Subject of Research: ESR2 promoter DNA methylation and mRNA expression in sheep ovaries during puberty onset

Article Title: ESR2 promoter methylation and mRNA expression patterns in Duolang sheep ovaries across pubertal stages

Article References: Gu, R., Liu, L., Wu, L., Wang, M., & Xing, F. (2026). ESR2 promoter methylation and mRNA expression patterns in Duolang sheep ovaries across pubertal stages. Frontiers in Animal Science, 7, Article 1932991. https://doi.org/10.3389/fanim.2026.1932991

Image Credits: AI Generated

DOI: 10.3389/fanim.2026.1932991

Keywords: DNA methylation, ESR2, estrogen receptor beta, puberty, Duolang sheep, ovary, granulosa cells, epigenetics, CpG islands, bisulfite sequencing, reproductive maturation, 5-Aza-dC

The central molecule in the study is anti-Müllerian hormone, or AMH, a glycoprotein produced by granulosa cells of growing follicles. AMH has long served clinicians as a blood biomarker of ovarian reserve, but it is far more than a passive readout. It is a key regulator of primordial follicle activation, restraining the recruitment of resting follicles into the growing pool and thereby helping to maintain the reserve over a female’s reproductive lifespan. What has remained unclear, the authors note, is which upstream pathways connect metabolic signaling to AMH regulation. Because ovarian aging is tightly intertwined with metabolic decline, that missing link matters enormously.

The researchers focused on peroxisome proliferator-activated receptor gamma, PPARγ, a nuclear receptor that acts as a ligand-activated transcription factor controlling genes involved in lipid metabolism and glucose homeostasis. PPARγ is the molecular target of thiazolidinediones, the class of insulin-sensitizing drugs that includes rosiglitazone. Crucially for this study, PPARγ is also expressed in ovarian granulosa cells and has been implicated in follicle development. The team hypothesized that activating this receptor would regulate AMH expression and, through it, the dynamics of primordial follicle regulation in the ovary.

To test the idea, the researchers combined three complementary experimental systems. Ovaries from 2-day-old neonatal mice were cultured ex vivo for up to 96 hours under control conditions or with rosiglitazone treatment. In parallel, 1-day-old neonatal mice were treated in vivo and analyzed seven days later. To capture age-dependent effects, young adult females aged 7 to 8 weeks and aged females aged 56 to 62 weeks received repeated treatment over a 21-day period, followed by ovulation induction, oocyte retrieval, and in vitro fertilization. Molecular, histological, and functional outcomes were assessed at predefined time points, and human granulosa-like cells were analyzed in vitro to check whether the signaling responses were conserved across species.

The molecular results were strikingly specific. PPARγ activation increased Amh expression together with the expression of AMH-associated transcription factors, including Sf1, Gata4, and Foxl2, without altering PPARγ mRNA levels, with statistical significance at P less than 0.05. Sf1, also known as Nr5a1, Gata4, and Foxl2 form the transcriptional circuitry that granulosa cells use to maintain AMH production, so the coordinated upregulation suggests PPARγ acts on the regulatory network rather than on a single gene in isolation. These responses were consistently observed across independent biological replicates, which the authors say supports the robustness and reproducibility of the signaling effects.

Even more intriguing was the pathway the team identified downstream of PPARγ. Activation selectively enhanced phosphorylation of STAT3 at serine 727, both in mouse ovaries and in human granulosa-like cells, at P less than 0.01. Total STAT3 abundance and phosphorylation at tyrosine 705, the site classically associated with cytokine-driven transcription, remained unchanged. This selectivity is technically meaningful: serine 727 phosphorylation modulates STAT3’s transcriptional activity independently of the canonical Tyr705 pathway, implying that PPARγ engages a metabolic branch of STAT3 signaling in granulosa cells. The consistency of this response across mouse and human cell systems strengthens the case that the mechanism is not a rodent quirk.

The functional outcomes in aged mice are what will make the study travel far beyond specialist journals. After repeated rosiglitazone treatment over 21 days, aged females showed increased primordial follicle numbers and reduced zona pellucida remnants, the microscopic debris of degenerated follicles that accumulates as the ovary ages. Treatment also improved oocyte quality and blastocyst development after in vitro fertilization, with significance at P less than 0.05. In young mice, by contrast, treatment effects were minimal, indicating an age-dependent responsiveness to PPARγ activation. The aged animals, whose ovaries were in metabolic and functional decline, were the ones that benefited.

That age-dependent pattern carries both promise and caution. On the promise side, it suggests that PPARγ modulation acts on a reserve that has become dysregulated with age, potentially restoring restraint on primordial follicle activation through the AMH pathway rather than creating new eggs. On the caution side, the authors are explicit that mice and a human granulosa-like cell line were studied without any genetic manipulation of PPARγ, and that caution is warranted when extrapolating the results to clinical contexts. Rosiglitazone itself has a complicated clinical history, having been restricted in some markets over cardiovascular safety concerns, so any translation to human fertility treatment would require careful dose, safety, and efficacy studies.

The study’s design also deserves attention for what it avoided. Rather than overexpressing or deleting PPARγ, the researchers used pharmacological activation in intact ovaries, ex vivo and in vivo, which preserves the natural cellular context of granulosa cells, oocytes, and stromal compartments. The combination of ex vivo neonatal ovary culture, in vivo neonatal and aged mouse models, and in vitro human granulosa-like cell analyses allowed the team to triangulate the mechanism from several angles. All animal experiments were approved by the Institutional Animal Care and Use Committee of CHA University, and the work was funded by the Korean Health Technology R&D Project through KHIDI and by a National Research Foundation of Korea grant.

For a field searching for interventions that slow ovarian aging, the findings support a regulatory role for PPARγ in linking metabolic signaling to AMH regulation and early follicle dynamics, providing mechanistic insights into age-dependent changes in ovarian function. The next questions are predictable: whether the STAT3 Ser727 branch can be targeted more precisely than PPARγ itself, whether the improved blastocyst rates translate into live births, and whether aged human ovaries respond the way aged mouse ovaries did. What is already clear is that the boundary between metabolism and reproductive aging is thinner than once believed, and that a drug class designed for insulin resistance may have something to say about the biology of the biological clock.

Subject of Research: Reproductive biology

Article Title: PPARγ modulation enhances ovarian function and oocyte competence in aged mice

Article References: Park, M. S., Hwang, J. Y., Kim, J. H., Yoon, J. A., Eum, J. H., Lee, W. S., & Yoon, S. Y. (2026). PPARγ modulation enhances ovarian function and oocyte competence in aged mice. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02314-4

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02314-4

Keywords: PPARγ, anti-Müllerian hormone, ovarian reserve, ovarian aging, oocyte quality, rosiglitazone, STAT3 signaling, in vitro fertilization, granulosa cells, Journal of Ovarian Research, PPAR, modulation

PMOS is far more than a reproductive inconvenience. The condition, which affects an estimated one in ten to one in five women worldwide depending on the diagnostic criteria applied, weaves together irregular ovulation, elevated male hormones called androgens, insulin resistance, obesity and long-term risks including type 2 diabetes and cardiovascular disease. In 2026, an international consensus process published in The Lancet formally renamed the condition to reflect its true nature as a multi-system endocrine and metabolic disorder rather than a purely gynaecological one. Yet despite decades of research, the initiating mechanisms that tie these seemingly disparate defects together have remained elusive, leaving clinicians to manage symptoms rather than root causes.

The new study began with a clue from clinical chemistry. Analysing follicular fluid, the nutrient-rich liquid that surrounds developing eggs within the ovary, the researchers found that the metabolism of methionine, an essential amino acid that fuels a cellular process called methylation, was dysregulated in women with PMOS. They also observed that nicotinamide metabolism was disturbed, and that NNMT, the enzyme responsible for methylating nicotinamide, was markedly elevated in granulosa cells, the somatic cells that nurture developing follicles and support ovulation. The pattern held up across public gene-expression datasets and an expanded clinical cohort of 21 patients with PMOS compared with 16 controls, and NNMT levels correlated with serum anti-Müllerian hormone concentrations and the ratio of luteinizing hormone to follicle-stimulating hormone, both hallmarks of the syndrome.

What makes NNMT so consequential is its peculiar biochemistry. The enzyme consumes methyl groups from S-adenosylmethionine, the universal methyl donor of the cell, and transfers them to nicotinamide, producing N1-methylnicotinamide. In doing so, NNMT acts as what researchers have called a metabolic methylation sink: it drains the cell’s pool of available methyl groups, starving the machinery that decorates histones, the protein spools around which DNA is wound. When histone methylation falters, genes that should be silenced can spring into activity. NNMT had previously been implicated in epigenetic remodelling in cancer cells and in metabolic dysfunction in the liver, but its role in the ovary had never been systematically explored.

To test whether NNMT could actually drive disease, the team used an adeno-associated virus to overexpress Nnmt specifically in the granulosa cells of mice. The results were striking. The animals developed a constellation of PMOS-like features, including disrupted oestrous cycles, altered follicle development, elevated luteinizing hormone and an increased luteinizing hormone to follicle-stimulating hormone ratio, mirroring the endocrine profile seen in affected women. Transcriptomic analysis of the ovaries revealed that the gene programmes activated by Nnmt overexpression overlapped significantly with genes known to respond to luteinizing hormone and to dihydrotestosterone, a potent androgen, suggesting that the enzyme had pushed the ovary into an androgen-dominated state.

The mechanistic core of the study lies in a specific histone mark: trimethylation of lysine 27 on histone H3, abbreviated H3K27me3. This mark, deposited by the enzyme EZH2 as part of the Polycomb repressive complex 2, is a classic silencing signal that keeps developmental and metabolic genes in check. The researchers showed that NNMT overexpression in granulosa cells reduced H3K27me3 across the genome, and that pharmacologically blocking EZH2 with the inhibitor GSK343 reproduced the same PMOS-like hormonal and ovarian phenotypes in mice. In other words, the loss of this single repressive mark was sufficient to push the ovary toward the disease state, establishing H3K27me3 as a critical downstream effector of NNMT.

Which gene, then, does the loss of H3K27me3 unleash? The team’s search converged on retinoic acid receptor beta, or RARB, a nuclear receptor whose expression rose when the repressive mark was stripped away. RARB had previously been linked to the regulation of human androgen biosynthesis, and the new data confirmed its role: when the researchers overexpressed Rarb in primary theca-interstitial cells, the ovarian cells responsible for producing androgens, testosterone accumulated in the culture medium and steroidogenesis-related genes were upregulated. In mice, ovarian Rarb expression correlated with both Nnmt levels and serum testosterone concentrations, and granulosa cells from women with PMOS showed elevated RARB compared with controls.

Perhaps the most compelling aspect of the findings is that the circuit does not merely run downhill from enzyme to hormone. The researchers demonstrated that androgen itself suppresses H3K27me3 in granulosa cells, feeding back on the very epigenetic landscape that unleashed RARB in the first place. This creates a self-reinforcing feedforward loop: NNMT erodes histone methylation, which activates RARB, which drives androgen synthesis, which further erodes histone methylation. Once the loop is established, the cell becomes locked into a hyperandrogenic identity that persists even if the original metabolic trigger subsides, providing a plausible explanation for the chronicity of PMOS and for why the disorder can be transmitted across generations through epigenetic mechanisms, as earlier work in mice and sheep has suggested.

Crucially, the loop appears to be breakable. When the researchers treated mice with a DHEA-induced model of the syndrome using a pharmacological inhibitor of NNMT, H3K27me3 levels were restored, the RARB-androgen circuit was disrupted, and both the metabolic and hormonal phenotypes improved. Glucose tolerance normalized, oestrous cycles stabilized, and serum concentrations of testosterone, anti-Müllerian hormone and luteinizing hormone all declined. Parallel experiments in mice lacking Nnmt specifically in granulosa cells confirmed that the enzyme’s presence was required for the full manifestation of the DHEA-induced phenotype. NNMT inhibitors have already been developed and tested in other contexts, including obesity and metabolic syndrome in preclinical models, which raises the prospect of repurposing or refining these compounds for PMOS.

The study does not claim to have solved PMOS in its entirety. The syndrome is heterogeneous, with distinct genetic subtypes and environmental contributions, and mouse models capture only part of the human condition. Human sequencing data from the study are available only under controlled access, and translating findings from granulosa cells in mice to the ovaries of diverse patient populations will require further validation. Nevertheless, by identifying the NNMT-H3K27me3-RARB-androgen axis as a mechanistic nexus linking methionine metabolism, epigenetic dysregulation and excess androgen production, the work provides both a unifying framework for understanding how reproductive, endocrine and metabolic defects intertwine, and a concrete, druggable target for interventions that could, for the first time, address the epigenetic roots of the disorder rather than merely its symptoms.

Subject of Research: The role of NNMT-driven epigenetic remodelling in hyperandrogenism of polyendocrine metabolic ovarian syndrome

Article Title: NNMT enhances hyperandrogenism in polyendocrine metabolic ovarian syndrome through epigenetic remodelling

Article References: Huang, W., Yu, C., Wang, Y., Sun, N., Wang, L., Ren, J., Xu, Y., Guo, X., Li, X., Mao, Y., Pan, J., Liu, T., Yang, H., & Huang, H. (2026). NNMT enhances hyperandrogenism in polyendocrine metabolic ovarian syndrome through epigenetic remodelling. Nature Metabolism. https://doi.org/10.1038/s42255-026-01625-6

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01625-6

Keywords: NNMT, polyendocrine metabolic ovarian syndrome, PCOS, epigenetics, H3K27me3, RARB, hyperandrogenism, granulosa cells, methionine metabolism, androgen biosynthesis, EZH2, Nature Metabolism

The biological rationale rests on three interconnected processes that drive ovarian aging. The first is oxidative stress and mitochondrial dysfunction: oocytes and their surrounding granulosa cells depend heavily on mitochondrial metabolism, and when redox homeostasis falters, both follicular development and oocyte quality suffer. Human ovarian tissue from older women shows oxidative damage and altered nicotinamide, purine, and glutathione metabolism, while mice lacking the antioxidant-regulating gene Gclm lose their primordial follicle pool at an accelerated rate. The second process is chronic immune-inflammatory remodeling of the ovarian microenvironment, with aged ovaries accumulating macrophages, CD4-positive T cells, and inflammatory mediators such as interleukin-1, tumor necrosis factor-alpha, and the NLRP3 inflammasome. The third is dysregulated granulosa-cell death, which starves growing follicles of metabolic and endocrine support and pushes them toward atresia.

What makes the gut relevant to all three processes is its capacity to generate systemic signals. Short-chain fatty acids produced by fiber-fermenting bacteria can be sensed through G-protein-coupled receptors on granulosa cells, where butyrate alters histone acetylation, steroidogenesis, and mitochondrial dynamics. In animal work, microbiota-derived short-chain fatty acids also act indirectly, activating GPR43 receptors in the fat tissue surrounding the ovary, triggering leptin secretion, and reducing granulosa-cell apoptosis. Bile acids, another microbiota-modified signaling class, connect the gut to the ovary through the GATA3–interleukin-22 pathway, while lipopolysaccharide leaking across a compromised intestinal barrier can drive ovarian inflammation via the TLR4–NF-κB route. Tryptophan metabolism and microbial modification of reproductive steroids add further layers to this communication network.

The most compelling preclinical evidence comes from studies that go beyond correlation. In a mouse model of premature ovarian insufficiency induced by Tripterygium glycosides, the probiotic strain Lactobacillus salivarius Li01 improved hormone profiles, preserved follicles, and reduced ovarian inflammatory injury. Crucially, these protective effects largely vanished in germ-free mice, demonstrating that the strain’s benefit depended on an intact gut microbial ecosystem. In a separate model of cisplatin-induced ovarian injury, Limosilactobacillus reuteri DSM 17938 preserved follicular reserve, and mechanistic experiments traced the effect to its associated metabolite beta-resorcylic acid, which suppressed nuclear SOX7 accumulation and downstream BAX-mediated granulosa-cell apoptosis.

Fecal microbiota transplantation experiments push the story closer to genuine reproductive aging. Transplanting gut microbes from young donors into reproductively aged mice improved ovulation, oocyte quality, spindle integrity, and litter outcomes, with multi-omics analyses implicating a Bacteroides caecimuris–glutamate pathway that supported mitochondrial function in aged oocytes. Oral administration of Parabacteroides johnsonii in middle-aged mice improved ovarian reserve and reduced follicular atresia. Yet the review’s authors are careful to note that these interventions are not defined probiotic products, and that the benefits of young-donor FMT faded substantially within about thirty days.

The human evidence tells a more sobering story. Most clinical trials have been conducted in polycystic ovary syndrome, a related but distinct ovarian dysfunction. Two recent meta-analyses reported statistically significant pooled improvements in fasting insulin, testosterone, and lipids with microbiota-targeted supplementation, but the review shows they share most of their primary studies and should not be treated as independent replications. Their outcomes measure metabolic and endocrine features of PCOS, not the rate at which the follicular reserve declines. In menopause-related populations, randomized trials of Lactobacillus acidophilus YT1 and of a three-strain KABP formulation improved symptom and quality-of-life scores, but neither demonstrated changes in ovarian-reserve markers such as anti-Müllerian hormone or antral follicle count. Notably, the two KABP trials involved the same formulation, overlapping industry-affiliated investigators, and industry sponsorship, so they extend rather than independently confirm the dataset.

The review’s structured search of PubMed, Web of Science, and clinical trial registries, spanning more than 4,700 retrieved records and 75 unique registry entries, found no completed randomized human trial designed to test whether probiotics slow longitudinal physiological ovarian-reserve decline. Registered studies in premature ovarian insufficiency and diminished ovarian reserve do include AMH and follicle-count outcomes, but these are disease-specific or short-term endpoints, not demonstrations of a reduced rate of age-related follicular depletion. A trial of Limosilactobacillus reuteri NCU-37 in infertile women with leuprorelin-induced perimenopausal symptoms reported higher AMH and estradiol after four weeks, but the authors of the review caution that reversible pharmacological suppression of the hypothalamic–pituitary–ovarian axis is a very different physiological state from natural reproductive aging.

Translation also faces practical hurdles that are often glossed over in popular coverage. Probiotic effects are highly strain-, dose-, and host-dependent, and cannot be generalized across preparations. Animal doses cannot be linearly converted into human-equivalent colony-forming units, because CFU counts quantify viable organisms rather than a systemically absorbed chemical exposure, and activity depends on strain identity, formulation, viability during storage and gastrointestinal transit, and host context. Safety, too, must be assessed strain by strain: opportunistic infections have been reported in severely immunocompromised patients, and regulatory frameworks such as the European Qualified Presumption of Safety impose strain-specific qualifications. The review also highlights a surprising twist on the assumption that an aged microbiome is uniformly harmful: transplanting microbiota from estropausal donors into young adult mice unexpectedly improved several ovarian health measures, suggesting some late-life microbial changes may be compensatory rather than damaging.

The authors’ conclusion is measured but firm. The gut–ovarian axis is biologically plausible, experimentally testable, and increasingly supported by mechanistically rigorous animal studies that use germ-free conditions, metabolite rescue, and receptor manipulation to establish causality. But improving an ovarian phenotype in an induced disease model is not the same as delaying physiological ovarian aging in women, and no human evidence currently supports the latter claim. The priority, they argue, is not simply more probiotic trials but adequately powered, prospectively registered, double-blind, placebo-controlled studies of well-characterized strains in clearly defined reproductive-aging populations, with prespecified ovarian endpoints, longitudinal follow-up, and mechanistic biomarkers built in from the start. Until such trials are completed, probiotic functional foods should be regarded as promising research candidates for female reproductive health, not established interventions for extending reproductive lifespan.

Subject of Research: Probiotic modulation of the gut–ovarian axis in female reproductive aging

Article Title: Modulating the Gut–Ovarian Axis: Mechanistic Rationale and the Limits of Current Evidence for Probiotics in Female Reproductive Aging

Article References: Chen, M., Su, Q., Sun, M., Zhang, H., Xu, J., Zhang, C., & Wang, Y. (2026). Modulating the Gut–Ovarian Axis: Mechanistic Rationale and the Limits of Current Evidence for Probiotics in Female Reproductive Aging. Food Science & Nutrition, 14(10), Article e72454. https://doi.org/10.1002/fsn3.72454

Image Credits: AI Generated

DOI: 10.1002/fsn3.72454

Keywords: gut-ovarian axis, ovarian aging, probiotics, ovarian reserve, microbiota, granulosa cells, short-chain fatty acids, bile acids, premature ovarian insufficiency, PCOS, menopause, fecal microbiota transplantation

The research, led by Yao Peng and Yong Tan of Nanjing University of Chinese Medicine together with colleagues, set out to map what actually happens inside ovarian tissue after repeated exposure to cyclophosphamide. Working with a rat model of multiple drug exposures, the team combined two powerful approaches: they measured the activity of circadian rhythm genes in the ovary, and they ran proteomic analysis to survey the full complement of proteins whose abundance shifted after treatment. The results converged on a surprising culprit. The ovaries of drug-exposed animals showed abnormal expression of circadian rhythm genes, and proteomics revealed a dramatic drop in one protein in particular: riboflavin kinase, abbreviated RFK, the enzyme that initiates the cellular processing of vitamin B2.

That finding might sound obscure, but riboflavin kinase sits at the head of a metabolic pathway with far-reaching consequences. The enzyme converts riboflavin, the vitamin better known as B2, into flavin mononucleotide, which is then elaborated into flavin adenine dinucleotide, or FAD, one of the most indispensable cofactors in biology. FAD participates in hundreds of redox reactions, shuttling electrons through the metabolic machinery that keeps cells alive. The new study adds a second, less appreciated role to that list: FAD is also a structural partner for the circadian clock, because it competes with the clock proteins cryptochrome 1 and 2 for binding to the ubiquitin E3 ligase, the cellular machine that tags proteins for destruction.

Here is where the chemistry becomes elegant. Cryptochromes are the workhorse repressors of the mammalian circadian oscillator, the proteins that help cells keep a roughly 24-hour rhythm of gene activity. Like all proteins, they are constantly being built and broken down, and the ubiquitin E3 ligase is responsible for their degradation. FAD competes with the cryptochrome proteins for access to that ligase, which means that when FAD levels are adequate, the degradation machinery is partially occupied and the cryptochromes survive longer, stabilizing the clock. When FAD runs short, the ligase turns its full attention to cryptochrome 1 and 2, and the clock proteins are chewed up faster than the cell can replace them.

The rat experiments showed precisely this sequence unfolding after cyclophosphamide exposure. Riboflavin kinase expression fell, riboflavin metabolism faltered, FAD synthesis was inhibited, and the cryptochrome proteins were degraded at an accelerated rate. The circadian rhythm regulation of the ovary, a tissue whose follicular development, hormone secretion and ovulation are all coordinated by daily molecular rhythms, fell into disarray. In other words, the chemotherapy drug was not only attacking the DNA of dividing granulosa cells; it was quietly dismantling the metabolic and temporal infrastructure those cells depend on to function.

To test whether the connection was causal rather than coincidental, the researchers turned to molecular experiments in which they knocked down riboflavin kinase directly. The results reinforced the model. Suppressing the enzyme lowered levels of FAD synthase, the downstream enzyme that completes FAD production, and it worsened the degradation of cryptochrome 1 and 2. Circadian rhythm regulation was disrupted, and the consequences rippled into the function of ovarian granulosa cells, the somatic cells that nurse developing follicles and produce the hormones essential for fertility. With their clock destabilized and their metabolism compromised, the granulosa cells declined, and ovarian aging accelerated.

The most clinically tantalizing result came from the rescue experiment. When the researchers supplemented the system with FAD, the cascade of damage was mitigated. Restoring the flavin cofactor eased the pressure on the cryptochrome proteins, helped re-establish circadian regulation and protected granulosa cell function. In the framework of the study, FAD supplementation acted as a counterweight to the riboflavin metabolism defect that cyclophosphamide had created, suggesting a potential strategy for shielding the ovary during chemo. The authors conclude that cyclophosphamide can impair ovarian function by causing dysregulation of riboflavin metabolism, which in turn drives abnormal circadian rhythms.

The implications extend beyond oncology. Premature ovarian insufficiency affects roughly one percent of women and carries consequences that reach far beyond fertility, including bone loss, cardiovascular risk and psychological distress. If a substantial share of chemotherapy-induced ovarian damage is mediated through a metabolic cofactor rather than through DNA strand breaks alone, then the protective options broaden considerably. Dietary and pharmacological interventions aimed at preserving riboflavin metabolism, or at stabilizing cryptochrome proteins directly, could in principle complement the existing approaches to fertility preservation, which currently rely on egg or embryo freezing and on temporary ovarian suppression with hormonal analogs during treatment.

The study also adds the ovary to a growing list of tissues whose health appears to depend on the integrity of their peripheral circadian clocks. Circadian biologists have shown that nearly every organ runs its own internal timing system, synchronized by the brain’s master clock but capable of autonomous oscillation, and that disrupting these local clocks impairs tissue function. The ovary is an especially rhythm-sensitive organ: follicle maturation, steroidogenesis and ovulation follow daily patterns, and granulosa cells express clock genes whose cycling is thought to coordinate these processes. A chemotherapeutic agent that destabilizes cryptochrome proteins in granulosa cells is therefore attacking the ovary at a level that standard genotoxicity models never captured.

As with any animal study, the road from rat ovaries to human clinics is long, and the findings, published open access with support from the National Natural Science Foundation of China, will need validation in human ovarian tissue and eventually in patients. The dosing, timing and safety of FAD supplementation alongside chemotherapy remain to be established, and it is far too early for patients undergoing cyclophosphamide treatment to draw practical conclusions. But the study reframes a familiar hazard in a new light. A drug long understood as a DNA-damaging agent now appears to sabotage the ovary through a second route, by starving it of a vitamin-derived cofactor that keeps its cellular clocks running, and that second route, unlike DNA damage itself, may be one medicine can actually repair.

Subject of Research: Mechanisms of cyclophosphamide-induced ovarian damage via riboflavin metabolism and circadian rhythm disruption

Article Title: Cyclophosphamide as a reproductive hazard: disrupted riboflavin metabolism and circadian rhythms drive ovarian decline

Article References: Peng, Y., Ma, Z., Hu, D., Wu, S., Shi, J., Chen, J., & Tan, Y. (2026). Cyclophosphamide as a reproductive hazard: disrupted riboflavin metabolism and circadian rhythms drive ovarian decline. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02293-6

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02293-6

Keywords: cyclophosphamide, ovarian aging, premature ovarian insufficiency, riboflavin kinase, FAD, cryptochrome, circadian rhythm, granulosa cells, chemotherapy, fertility, vitamin B2, ovary

Female mammals are born with a finite, nonrenewable pool of oocytes established before birth. Most of these cells remain sealed inside primordial follicles, dormant and protected, forming the ovarian reserve that must last a lifetime. A small fraction is continually recruited into growth, becoming what the researchers call activated oocytes. These enter growing follicles, where they are supported by surrounding somatic granulosa cells, and progress through well-defined stages: primary, secondary, preantral and antral. Because every activated oocyte represents a permanent withdrawal from the reserve, the pace at which these cells are consumed directly determines how long a female stays fertile. Yet the dynamics of this consumption — whether activated oocytes march forward at a uniform speed or linger in certain stages — had remained largely unknown, because conventional histology and short-term labeling techniques cannot follow individual follicles over months.

To solve this problem, the team engineered mice carrying a Zp3-CreER^T2 driver crossed with a dual-fluorescent mTmG reporter. When the drug tamoxifen was administered at postnatal day 35, corresponding to young adulthood, only oocytes actively expressing the zona pellucida protein ZP3 — that is, activated oocytes — switched on membrane-bound green fluorescent protein, while dormant oocytes stayed red and unlabeled. Labeling efficiency peaked at 63.12 ± 5.59 percent three days after induction, giving the researchers a large, precisely marked cohort to track. They then examined ovaries at intervals across a full 12-month tracing window, covering the entire reproductive lifespan of a laboratory mouse.

The results were striking. Two months after labeling, 47.97 ± 11.61 percent of the marked oocytes were still detectable; after six months, 15.46 ± 4.48 percent remained. Remarkably, even a full year later, 4.17 ± 1.11 percent of the originally labeled oocytes were still present in the ovaries. These were not cellular relics: when the researchers superovulated females that had been traced for nine months, they recovered green-labeled eggs that fertilized in vitro at rates comparable to unlabeled controls — 61.76 ± 18.11 percent versus 68.08 ± 16.60 percent — and yielded healthy two-cell embryos, blastocysts and live offspring with normal growth and fertility. Natural mating experiments at six and nine months after labeling produced GFP-positive pups, confirming that these long-lived oocytes contribute to real, physiological reproduction rather than merely surviving in tissue sections.

Having established that activated oocytes can persist, the team mapped where in the follicle pipeline they linger. Primary follicles proved fleeting: labeled oocytes disappeared from this stage within 30 days of tagging, meaning the primary phase lasts at most about a month. Secondary and antral follicles, by contrast, harbored labeled oocytes throughout the entire 12-month observation period. Because roughly 80 percent of the long-lived labeled oocytes were consistently found in secondary follicles — defined as follicles with multiple layers of granulosa cells but no visible antral cavity — the researchers concluded that the secondary stage is the principal site of long-term oocyte residence. Its maximum lifespan must therefore be at least 11 months, while its minimum can be estimated at roughly two weeks, based on transplantation studies showing that secondary follicles reach the antral stage within that time. In other words, secondary follicle lifespan spans an extraordinary range, from a few estrous cycles to nearly the whole reproductive life of the animal.

That variability turned out to be functional. BrdU incorporation assays revealed that some secondary follicles contained granulosa cells proliferating vigorously, while others showed far lower division rates — heterogeneity absent from antral follicles, which grew rapidly and uniformly. The secondary follicle population, the authors propose, functions as a developmental buffer zone: a secondary ovarian reserve that throttles the rate at which activated oocytes are spent, balancing immediate fertility against reproductive longevity.

The buffering capacity is not fixed but adapts to circumstances. When the team labeled activated oocytes in 10-month-old mice — late reproductive age — the marked cells vanished within three months, indicating accelerated utilization as the reserve dwindles. To separate the effect of age from that of reserve size, the researchers surgically removed one ovary from young females, halving the reserve without aging the animal. Labeled oocytes in these half-reserve mice were depleted in about seven months, roughly half the lifespan seen in intact controls. The primary follicle stage, notably, remained capped at about one month in all conditions, pinpointing the secondary stage as the adjustable regulatory window. The ovary, it appears, senses its remaining capacity and speeds up or slows down oocyte consumption accordingly — a homeostatic strategy the authors suggest may be governed by endocrine feedback reflecting reserve size.

What molecular machinery allows an oocyte to idle for months? Quantitative single-oocyte proteomics on individual oocytes isolated from secondary follicles after five months of tracing identified more than 5,962 protein groups, with 5,240 passing quality control. Unsupervised clustering cleanly separated long-lived labeled oocytes from their shorter-lived unlabeled counterparts: the long-lived group showed 826 significantly downregulated proteins and only four upregulated ones. The suppressed proteins clustered in developmental and metabolic pathways, including the translation regulator LIN28A, the amino-acid transporter SLC7A5, fatty acid synthase, glutaminase, the mitochondrial fusion protein MFN2 and the pyruvate carrier MPC1. Direct measurements confirmed the picture: EU staining showed reduced nascent RNA synthesis and HPG staining showed reduced protein synthesis in long-lived oocytes, while the granulosa cells surrounding them proliferated more slowly. Longevity, in short, is achieved through metabolic quiescence — a coordinated shutdown of biosynthesis, mitochondrial activity and energy production.

The linchpin connecting oocyte state to follicle pace is the proprotein convertase FURIN. Long-lived oocytes expressed markedly less FURIN than their rapidly developing neighbors. When the team inhibited FURIN with the drug DRVC in cultured secondary follicles, growth was dramatically suppressed; conversely, mice lacking Furin specifically in oocytes accumulated secondary follicles and lacked antral ones. Xenotransplantation experiments sealed the case: secondary follicles from knockout mice transplanted into recipient ovaries remained stuck at the secondary stage even after four weeks, while control follicles had progressed to ovulation. FURIN’s substrate appears to be GDF9, an oocyte-secreted factor of the transforming growth factor beta family that carries a canonical FURIN cleavage motif. Western blotting showed that knockout oocytes contained normal amounts of GDF9 precursor but drastically reduced mature GDF9, and supplementing cultures with recombinant GDF9 partially rescued the follicle growth defect. The authors note that BMP15 and other factors likely contribute as well, since GDF9 rescue was incomplete. The model that emerges is one of coordinated pacing: oocytes with high FURIN release abundant mature GDF9, driving granulosa cell proliferation and rapid follicle growth, while oocytes with low FURIN hold their follicles in slow motion, extending their own lifespan.

The implications reach well beyond mice. If human folliculogenesis follows similar dynamics — and recent comparative work suggests substantial similarity between human and mouse ovaries — then eggs ovulated in a woman’s thirties may have been activated years or even decades earlier, overturning the textbook estimate that the full journey from activation to ovulation takes about a year. Because activated oocytes are metabolically active and in constant dialogue with their environment, prolonged residence could allow the gradual accumulation of damage from endocrine disruptors, metabolic disease and lifestyle exposures long before ovulation, offering a mechanistic explanation for the age-related decline in oocyte quality. The authors caution that their experimental mice lived in specific pathogen-free conditions that may have protected long-lived oocytes from the stresses of the outside world, and that human-focused studies are still needed. Even so, the identification of a tunable secondary-follicle buffer — and of FURIN-mediated GDF9 maturation as its molecular lever — points toward concrete strategies for fertility preservation, from modulating oocyte metabolic activity to adjusting follicular dynamics, in the effort to extend reproductive health.

Subject of Research: Developmental dynamics and lifespan regulation of activated oocytes and secondary follicles in the mouse ovary

Article Title: Heterogeneity in secondary follicle development buffers the lifespan of activated oocytes to optimize female fertility in mice

Article References: Liang, J., Yang, X., Li, Q., Li, L., Wang, G., Mu, L., Sun, N., Geng, K., Hu, X., Niu, S., Jia, L., Wang, Y., Xu, X., Li, Z., Wang, F., Zhang, Y., & Zhang, H. (2026). Heterogeneity in secondary follicle development buffers the lifespan of activated oocytes to optimize female fertility in mice. Nature Aging. https://doi.org/10.1038/s43587-026-01237-5

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01237-5

Keywords: oocytes, ovarian reserve, folliculogenesis, secondary follicles, FURIN, GDF9, lineage tracing, reproductive aging, fertility, metabolic quiescence, granulosa cells, Nature Aging

The form of cell death at the center of the study is cuproptosis, a regulated death program first described in 2022 and distinct from apoptosis, necroptosis, and ferroptosis. Cuproptosis is triggered when copper binds directly to lipid-acylated components of the tricarboxylic acid cycle inside mitochondria. That binding causes the lipoylated proteins to aggregate, overwhelming the cell’s protein quality control systems. At the same time, copper stress depletes iron-sulfur cluster proteins, which are essential cofactors for enzymes involved in respiration and DNA maintenance. The result is a catastrophic collapse of mitochondrial metabolism that cannot be rescued by ordinary antioxidant defenses.

Granulosa cells are particularly vulnerable to this kind of metabolic injury. These somatic cells surround the oocyte within the ovarian follicle, supplying it with energy substrates, biosynthetic precursors, and survival signals. Their own energy metabolism and intense biosynthetic activity depend heavily on healthy mitochondria, so any program that dismantles mitochondrial function strikes at the heart of what granulosa cells do. When granulosa cells die, the follicle becomes atretic and is ultimately lost from the reproductive pool, which is why understanding the triggers of granulosa cell death matters for fertility in livestock and, potentially, in humans.

The researchers began by examining atretic follicles from pigs, a species whose ovarian physiology closely mirrors that of humans in several respects. In the granulosa cells of these degenerating follicles, they found elevated levels of SLC31A1, the copper transporter responsible for importing copper into cells, along with increased copper concentrations in both the granulosa cells themselves and the surrounding follicular fluid. These changes were accompanied by a telling molecular signature: reduced abundance of FDX1, the protein whose presence is considered a prerequisite for cuproptosis, along with decreases in LIAS, an enzyme required for protein lipoylation, DLAT, a key lipoylated component of the pyruvate dehydrogenase complex, ACO2, an iron-sulfur-cluster-dependent enzyme of the TCA cycle, and POLD1, a DNA polymerase subunit that also relies on iron-sulfur clusters.

Perhaps most strikingly, the atretic follicles showed increased oligomerization of DLAT, meaning that multiple copies of this mitochondrial protein had clumped together, which is the hallmark biochemical event of cuproptosis. The diminished lipoylation signals in the same samples reinforced the picture of a mitochondrial metabolic apparatus coming apart under copper stress. Taken together, these observations suggested that copper overload is not merely a passive byproduct of follicular degeneration but may be an active driver of the granulosa cell loss that defines atresia.

To test this idea directly, the team turned to cultured granulosa cells and exposed them to copper sulfate. The treatment produced the expected cascade of damage: copper accumulated inside the cells, mitochondrial function deteriorated, and markers of cuproptosis-associated injury appeared. When the researchers applied ammonium tetrathiomolybdate, a clinical copper chelator, the damage was preferentially attenuated, confirming that the injury was specifically copper-dependent rather than a nonspecific toxic effect. This pharmacological validation is important because it establishes copper overload as a sufficient and specific trigger for the cell death program observed in the cultures.

The pivotal experiments involved spermidine, a polyamine found in foods ranging from wheat germ to aged cheese and long studied for its roles in autophagy, mitochondrial function, and anti-aging biology. When the researchers supplemented the copper-stressed granulosa cells with spermidine, mitochondrial dysfunction was substantially relieved. Conversely, when they depleted polyamines from the cells, the loss of iron-sulfur cluster proteins and lipoylated proteins became worse, indicating that endogenous polyamines provide a baseline level of protection against copper-driven mitochondrial collapse. In mice subjected to copper overload, spermidine supplementation likewise attenuated ovarian injury, extending the protective effect from cell culture to a whole-animal model.

The mechanistic explanation the authors propose centers on a regulatory axis involving a microRNA and its target. Spermidine treatment reduced the abundance of miR-194a-5p, a small regulatory RNA that suppresses the production of DLAT. With miR-194a-5p lowered, DLAT expression recovered, and downstream metabolic functions followed: pyruvate dehydrogenase activity was preserved, ATP production was maintained, and both NDUFS1, a component of mitochondrial respiratory complex I, and ACO2 activity were protected. In other words, spermidine appears to act upstream, releasing the brake that miR-194a-5p places on DLAT, thereby keeping the lipoylated machinery of oxidative metabolism intact and less susceptible to copper-induced aggregation.

This spermidine/miR-194a-5p/DLAT axis provides a coherent narrative linking copper stress to follicular atresia. Excess copper entering granulosa cells through SLC31A1 threatens to aggregate DLAT and destroy iron-sulfur proteins; miR-194a-5p, by suppressing DLAT, may compound the vulnerability; and spermidine intervenes by damping the microRNA and restoring the metabolic scaffold. The work also connects to a broader and rapidly growing literature on cuproptosis, including recent reports that copper-triggered death can arrest meiosis in oocytes, suggesting that copper homeostasis is emerging as a recurring theme in reproductive biology.

The practical implications are worth noting with appropriate caution. For livestock production, where follicular atresia directly limits reproductive efficiency, the study suggests that managing copper exposure and possibly supporting polyamine metabolism could help protect ovarian function. For human reproductive medicine, the pig model’s relevance makes the findings intriguing, though the authors and the field will need to establish whether the same axis operates in human granulosa cells and whether spermidine interventions are safe and effective in that context. What the study firmly establishes is a testable mechanism: a dietary-derived polyamine, a microRNA, and a lipoylated mitochondrial enzyme forming a regulatory circuit that determines whether copper stress becomes lethal. As cuproptosis research moves from cancer biology into physiology and agriculture, this work demonstrates that the copper cell death pathway is not just a laboratory curiosity but a process with real consequences for one of biology’s most economically and personally significant processes, the maintenance of the ovarian follicle reserve.

Subject of Research: Spermidine-mediated protection of ovarian granulosa cells from copper overload-induced cuproptosis via the miR-194a-5p/DLAT axis

Article Title: Spermidine attenuates copper overload-induced cuproptosis in porcine granulosa cells through the miR-194a-5p/DLAT axis

Article References: Wang, X., Jiang, D., Ling, W., Ji, C., Qi, Y., An, X., Li, S., Lu, L., Li, M., & Kang, B. (2026). Spermidine attenuates copper overload-induced cuproptosis in porcine granulosa cells through the miR-194a-5p/DLAT axis. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03379-2

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03379-2

Keywords: cuproptosis, spermidine, copper overload, granulosa cells, DLAT, miR-194a-5p, follicular atresia, mitochondrial dysfunction, SLC31A1, iron-sulfur cluster proteins, ovarian follicle, cell death

Figla, short for factor in the germline alpha, is a basic helix-loop-helix transcription factor expressed almost exclusively in oocytes. It first earned its reputation in the late 1990s, when researchers showed that it coordinates the expression of the zona pellucida genes, the family of genes encoding the protective glycoprotein shell that surrounds every egg. Later work proved that Figla is not merely a structural coordinator but an indispensable architect of folliculogenesis itself: mice lacking Figla fail to form primordial follicles, and their oocytes are progressively lost after birth. In humans, mutations in FIGLA have been identified in patients with premature ovarian failure, and increased FIGLA expression is associated with the moment primordial follicles begin to form in the human fetal ovary. What has remained elusive, however, is a comprehensive picture of which genes Figla actually controls to accomplish these feats.

To close that gap, the team generated a Figla knockout mouse model and examined what happens to ovarian development when the transcription factor is removed. Their timing analysis showed that Figla is highly expressed in late embryonic and early postnatal ovaries, precisely the period when primordial follicle assembly takes place. When Figla was deleted, the disruption was concentrated in this perinatal window: the assembly of primordial follicles was primarily impaired, and the knockout ovaries suffered progressive oocyte loss as development proceeded. This phenotype is consistent with the known biology of the gene but, crucially, the researchers did not stop at confirming the knockout effect. They set out to find what Figla might be acting upon.

The search for downstream targets relied on chromatin immunoprecipitation sequencing, or ChIP-seq, a technique that allows researchers to map, across the entire genome, the DNA regions where a given protein physically binds. By pulling down FIGLA-associated chromatin from ovarian tissue and sequencing the captured fragments, the team identified the genomic sites the transcription factor occupies in vivo. Motif analysis of these binding regions then asked whether the sequences showed the characteristic signature of FIGLA recognition, and promoter activity assays tested whether candidate regulatory regions could actually drive gene expression in a FIGLA-dependent manner. Together, these three lines of evidence converged on one particularly interesting candidate: Ywhab, the gene encoding YWHA-beta, one member of the 14-3-3 family of phosphoserine-binding proteins.

The 14-3-3 proteins are a family of highly conserved scaffolding molecules that recognize and bind specific phosphorylated motifs on other proteins, thereby acting as molecular adapters that relay signals, control protein localization and modulate enzyme activity. YWHA-beta, the isoform encoded by Ywhab, has well-documented roles in two signaling circuits that are directly relevant to cell survival and proliferation. The first involves the RAF kinases, where 14-3-3 dimers serve as essential cofactors for RAF kinase activity, a critical node at the top of the mitogen-activated protein kinase cascade that culminates in the phosphorylation of ERK, or extracellular signal-regulated kinase. The second involves BAD, a pro-apoptotic member of the BCL-2 family. When BAD is phosphorylated at a specific serine residue, 14-3-3 proteins bind it and sequester it away from the mitochondria, preventing it from triggering the apoptotic machinery. In this way, 14-3-3 proteins function as a molecular switch that tips the balance between cell survival and programmed cell death.

Armed with the ChIP-seq, motif and promoter data, the researchers moved into functional testing. They used KGN cells, a human granulosa-like tumor cell line that expresses a functional follicle-stimulating hormone receptor and has become a standard model for studying granulosa cell biology. When the team overexpressed Figla in these cells, Ywhab expression rose, and the cells displayed measurably greater growth activity and migration. Alongside these behavioral changes, the overexpression coincided with increased ERK phosphorylation and alterations in the levels of apoptosis-related markers, including BAD, BCL-2 and BAX, the canonical trio that governs mitochondrial apoptosis. The picture that emerged was of Figla pushing granulosa cells toward a more proliferative, more migratory and more survival-oriented state, with Ywhab sitting plausibly in the middle of that response.

The decisive experiment came next. If Ywhab were truly mediating Figla’s effects, then removing Ywhab should blunt those effects even when Figla is abundant. That is exactly what the team observed: when they knocked down Ywhab in the Figla-overexpressing KGN cells, the enhanced growth activity, the increased migration, the elevated ERK phosphorylation and the changes in the BAD, BCL-2 and BAX markers were all attenuated. In other words, Ywhab was not merely a passive readout of Figla activity but appeared to be functionally required for the cellular consequences of that activity, at least in this cell culture system.

To connect the cell culture findings back to intact ovarian physiology, the researchers performed Western blot analysis on ovarian tissue from their mouse models. In the Figla-deficient ovaries, they found a reduced ratio of phosphorylated ERK to total ERK, indicating dampened activity of the MAPK signaling pathway, together with an increased ratio of phosphorylated BAD to total BAD. The direction of these changes in the knockout tissue mirrors what one would predict if Figla normally drives Ywhab-dependent signaling: loss of Figla weakens the pro-survival, pro-proliferative signaling axis, and the apoptotic balance shifts in a way that is consistent with the progressive oocyte loss seen in the knockout animals. The convergence of the in vitro and in vivo data strengthens the case that the Figla-Ywhab relationship is not an artifact of the cell line.

The significance of this work lies in how it links two levels of biology that are usually studied separately. On one level, Figla is a transcription factor operating inside the oocyte, orchestrating the gene expression program that allows follicles to assemble. On another level, the ERK pathway and the BCL-2 family are signaling systems that govern the behavior of granulosa cells and the survival of the oocyte-granulosa unit. By proposing Ywhab as a bridge between these levels, the study suggests a mechanism through which an oocyte-specific transcription factor could influence the signaling environment of the surrounding somatic cells during the critical perinatal period. Given that programmed cell death and germ cell loss are recognized features of primordial follicle assembly, and that ERK signaling in granulosa cells has been shown in earlier work to be essential for female fertility, a transcriptional link connecting these processes is exactly the kind of finding the field has been looking for.

The authors themselves are careful about the limits of the study. Ywhab is presented as a candidate downstream gene, not a definitively validated direct target, and the functional experiments were conducted in a granulosa cell line rather than in oocytes or intact follicles. The knockout phenotype, while striking, does not by itself prove that every aspect of it flows through Ywhab. Extending these findings to the broader process of ovarian reserve establishment, or to premature ovarian insufficiency in patients, will require further validation, ideally including direct demonstration of FIGLA binding to the Ywhab promoter in oocytes, genetic rescue experiments and analysis in human tissue. Nevertheless, the study provides a concrete and testable hypothesis: that the lifespan-defining act of assembling the ovarian reserve depends, in part, on a transcription factor in the egg switching on a signaling adaptor in its cellular neighborhood. If that hypothesis holds up, genes in the Figla-Ywhab-ERK axis could become markers for ovarian reserve quality and, one day, targets for interventions aimed at protecting the follicle pool in women at risk of premature ovarian insufficiency.

Subject of Research: The role of the transcription factor Figla and its candidate downstream target Ywhab in primordial follicle formation and ovarian reserve establishment

Article Title: Identification of Ywhab as a Candidate Downstream Target of Figla During Ovarian Reserve Establishment

Article References: Yang, L., Li, L., Shen, L., & Zhang, H. (2026). Identification of Ywhab as a Candidate Downstream Target of Figla During Ovarian Reserve Establishment. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02173-w

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02173-w

Keywords: Figla, Ywhab, ovarian reserve, primordial follicle, oocyte, granulosa cells, transcription factor, ERK signaling, apoptosis, premature ovarian insufficiency, ChIP-seq, 14-3-3 proteins

The construct, which the team calls SPHEGaT — spheroids of endocrine granulosa and theca cells — was built from primary human cells with careful attention to spatial organization. Granulosa cells, harvested from patients undergoing in vitro fertilization, expressed the aromatase enzyme CYP19A1 and the follicle-stimulating hormone receptor, marking them as the estrogen-producing core. Theca-like cells were differentiated from ovarian stromal cells isolated from postmenopausal donors, and they expressed CYP17A1 and CD13, consistent with their role in producing the androgens that granulosa cells then convert into estradiol. When the granulosa cells were seeded into low-attachment plates, they spontaneously self-aggregated into compact spheres within about three days. Theca-like cells were then added and progressively organized around the granulosa core, and a thin layer of collagen type I was deposited between the two compartments to mimic the follicular basement membrane. The result was a multilayered structure that echoes the compartmental arrangement of a native follicle.

Architecture, it turns out, is not merely cosmetic. After nine days of culture, the spheroids were remarkably healthy: quantitative analysis showed that 97.45 percent of the spheroid area remained viable, with no detectable focal necrosis. Dense three-dimensional aggregates often suffer from oxygen starvation in their cores, a problem the team checked directly by staining for HIF-2α, a marker of hypoxic stress. Only about 3 percent of nuclei were positive, and three-dimensional reconstruction confirmed the absence of a hypoxic core. Critically, the spheroids were functionally competent: the culture medium contained endogenous levels of estradiol at roughly 65 picograms per milliliter and progesterone at roughly 186 nanograms per milliliter. The spatially organized assembly had produced a living, breathing endocrine unit — one that secretes hormones the way a follicle does, rather than sitting passively in a bath of supplied steroids.

The decisive experiment came when the researchers coupled these spheroids to endometrial organoids, miniature gland-like structures grown from endometrial biopsies of women in their late twenties. Over six days of co-culture, the organoids underwent a visible transformation. Monocultured organoids retained mostly spherical, cyst-like shapes, but organoids exposed to the ovarian spheroids progressively developed folded, lobulated, and optically denser architectures. The proportion of folded organoids rose from about 2.4 percent in monoculture to nearly 13.7 percent in co-culture by day six, a highly significant difference. Circularity and solidity — geometric measures of how round and how smooth an organoid is — both declined over time in the co-cultured condition, indicating the emergence of irregular, invaginated epithelial structures reminiscent of glandular remodeling in the cycling endometrium.

What makes this remodeling striking is that it was not driven by proliferation. Ki67 staining, a standard marker of dividing cells, showed no significant difference between monocultured and co-cultured organoids, and total organoid area grew comparably in both conditions. The ovarian spheroids were not making the tissue grow faster; they were teaching it to reorganize. This mirrors in vivo physiology, where epithelial proliferation peaks during the estrogen-dominated proliferative phase and then stabilizes as progesterone steers the tissue toward secretory maturation. A trend toward reduced vimentin expression in co-cultured organoids further hinted at a dampening of epithelial-mesenchymal plasticity, a shift associated with secretory differentiation. In short, the ovarian signal was instructing architecture, not cell division.

At the molecular level, the co-culture produced clear evidence of endocrine reprogramming. Progesterone receptor expression surged in co-cultured organoids: only about 4.7 percent of nuclei were progesterone receptor-positive in monoculture, compared with roughly 40.5 percent after exposure to the spheroids. Estrogen receptor levels, by contrast, remained unchanged. The co-cultured organoids also upregulated a selective set of progesterone-responsive, secretory-phase genes, including PAEP, which encodes pregnancy-associated endometrial protein; SPP1, or secreted phosphoprotein 1; and HSD17B2, an enzyme involved in steroid metabolism. PAEP secretion, measured by ELISA, rose progressively in co-culture. Other receptivity-associated genes such as LIF, SOX17, GATA2, and AREG did not change significantly, indicating that the organoids entered a partial, progesterone-driven secretory state rather than acquiring the full implantation-window program — a limitation the authors attribute in part to the absence of an estrogen-priming phase in the current protocol.

One of the most intriguing observations was a hint of bidirectional communication. In the co-culture system, progesterone levels in the medium dropped markedly — to about 68 nanograms per milliliter compared with roughly 239 in spheroid monocultures — while estradiol levels stayed stable. This hormone-specific reduction suggests the endometrium may be actively metabolizing, taking up, or otherwise modulating ovarian progesterone output, echoing the known ability of uterine prostaglandins and other mediators to regulate luteal steroid production in vivo. The platform, in other words, does not just deliver hormones to the endometrium; it establishes a coupled endocrine axis in which hormone availability reflects ongoing integration between the two tissue compartments.

To test whether the morphogenic effects depended on steroids alone, the team performed an elegant depletion experiment. They treated spheroid-conditioned medium with dextran-coated charcoal, stripping out roughly 59 percent of the estradiol and 90 percent of the progesterone, and then compared three conditions: intact conditioned medium, depleted medium, and depleted medium with exogenous hormones added back. The results were unambiguous. Untreated conditioned medium induced the greatest epithelial folding over time. Depleted medium still supported a reduced but significant increase in folding — hinting at residual steroid activity or non-steroidal factors — but static hormone add-back failed entirely to restore the morphogenic phenotype and actually produced the lowest folding response of all. Organoids in the add-back condition grew larger but stayed smoother, suggesting that supraphysiologic or imbalanced steroid exposure biases tissue toward expansion rather than differentiation.

The implication is profound: the ovary’s instructive power over the endometrium cannot be reduced to a prescription of estradiol and progesterone. The intact follicle is a complex endocrine and paracrine factory, co-secreting inhibins and activins, growth factors such as EGF-like ligands and basic FGF, cytokines, metabolites, carrier proteins, and extracellular vesicles loaded with proteins, lipids, and regulatory RNAs. Many of these factors have been implicated in endometrial remodeling and implantation, and the temporal fluctuations, concentration gradients, and local metabolism inherent to an intact ovarian unit may be as important as any single molecule. Static hormone replacement, the study suggests, fundamentally cannot reproduce that context.

The researchers are candid about the limitations. The system models a progesterone-dominant environment without a preceding estrogen-priming phase, so it captures only part of the menstrual cycle’s proliferative-to-secretory transition. The co-culture lacks stromal decidualization, immune cells, vascular elements, and embryo-derived signals, all of which contribute to true uterine receptivity. The theca-like cells derive from postmenopausal donors, raising questions about age-related epigenetic carryover, and charcoal-dextran treatment may have altered non-steroidal components of the conditioned medium. Yet these caveats do not diminish the central achievement. The team has built the first spatially organized, fully human ovarian endocrine construct capable of directing endometrial morphogenesis in vitro, and shown that its effects exceed anything achievable with hormones alone. The platform opens a tractable window onto infertility, implantation failure, progesterone resistance, and endocrine disruption — and points toward a future generation of reproductive models built not on hormone recipes, but on reconstructed, talking tissues.

Subject of Research: Engineering spatially organized human ovarian spheroids to model ovarian-endometrial endocrine communication in vitro

Article Title: Spatially Organized Human Ovarian Spheroids Instruct Endometrial Morphogenesis

Article References: Sousa, M. J., Vriendt, S. D., Liu, L., Ruiz, T. F. R., Vankelecom, H., & Amorim, C. A. (2026). Spatially Organized Human Ovarian Spheroids Instruct Endometrial Morphogenesis. Advanced Science, 13(55), Article e76538. https://doi.org/10.1002/advs.76538

Image Credits: AI Generated

DOI: 10.1002/advs.76538

Keywords: ovarian spheroids, endometrial organoids, granulosa cells, theca-like cells, progesterone signaling, estradiol, steroidogenesis, reproductive biology, organ-on-a-chip, endometrial morphogenesis, infertility modeling, 3D cell culture